Schering Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Cropscience Ag

Bayer Intellectual Property Gmbh

Other

Bayer Aktiengesellschaft

Shering Ag

Schering Aktiengeseuschaft

Thomas Frenzel

Johannes Platzek

Heribert Schmitt-Willich

Hanns-Joachim Weinmann

Wolfgang Ebert

Ulrich Niedballa

Bernd Raduchel

Andreas Muhler

Gregor Jost

Jessica Lohrke

Bernd Misselwitz

Markus Berger

Christoph-Stephan Hilger

Olaf Panknin

Hubertus Pietsch

Wolfgang Schlecker

Christopher Hugh Rosinger

Lothar Willms

Elmar Gatzweiler

Ulrich Klar

Rolf Bohlmann

Joachim Kuhnke

Sven Ring

Frederik Menges

Klaus Bernhard Haaf

Detlev Suelzle

Steffen Borden

Katja Prelle

Bernd Radüchel

Monika H Schmitt

Sven Wittrock

Hans-Peter Muhn

Jan Hübner

Dieter Feucht

Heinz Kehne

Martin Jeffrey Hills

Jan Dittgen

Ines Heinemann

Bernd Raduechel

Pierre-Yves Coqueron

Heinz Gries

Marie-Claire Grosjean-Cournoyer

Philippe Rinolfi

Mazen Es-Sayed

Dirk Schmutzler

Stephane Brunet

Helene Lachaise

Hans Bauer

Thomas Brumby

Wolfgang Halfbrodt

Isolde Haeuser-Hahn

Stephen David Lindell

Arounarith Tuch

Jacky Vidal

Simon Anthony Herbert

Jan Peter Schmidt

Bernd Rad&uuml;chel

Stephan Holzschuh

Bernd Rad{umlaut Over (u)}chel

Andreas Mühler

Klaus Nickisch

Isolde Häuser-Hahn

Hansjoerg Dietrich

Hansjörg Dietrich

Gabriele Schuhmann-Giampieri

Detlev Sülzle

Orlin Petrov

Hubert Vogler

Heiko Schirmer

Jean-Claude Hilscher

Birgit Kuhn

Jan Huebner

Hans Peter Muhn

Günther Michl

Andreas M&uuml;hler

Andreas M{umlaut Over (u)}hler

Philipe Rinolfi

Claudia Green

Detlev Sulzle

An aqueous pharmaceutical composition including compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Gadolinium chelate compounds for use in magnetic resonance imaging

The present disclosure relates to a liquid pharmaceutical formulation comprising a DO3A-derived tetra-chelate of formula (I), in which M is an ion of a paramagnetic metal, preferably a Gdion, and R, R, R, Rand Rare as defined in the claims, in a pharmaceutical acceptable solvent. The present disclosure also relates to a method of preparation of said liquid pharmaceutical formulation and to a method of imaging involving said liquid pharmaceutical formulation.

Formulation of contrast media and process of preparation thereof

The present disclosure relates to a liquid pharmaceutical formulation comprising a DOSA-derived tetra-chelate of formula (I), in which M is an ion of a paramagnetic metal, preferably a Gdion, and R, R, R, Rand Rare as defined in the claims, in a pharmaceutical acceptable solvent. The present disclosure also relates to a method of preparation of said liquid pharmaceutical formulation and to a method of imaging involving said liquid pharmaceutical formulation.

The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging

A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents. 

A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[{2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl} amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Herbicidally and fungicidally active 3-heteroarylisoxazoline-5-carboxamides and 3-heteroarylisoxazoline-5-thioamides of the formula (I) are described.  In this formula (I), R represents radicals such as hydrogen, halogen and organic radicals such as substituted alkyl. A is a bond or a divalent unit. Y is a chalcogen.

Herbicidally and fungicidally active 3-heteroaryl-isoxazoline-5-carboxamides and 3-heteroaryl-isoxazoline-5-thioamides

The present invention relates to novel isoxazoline carboxamide derivatives, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials.

Nitrogen-containing heterocyclic compounds for plant disease control

3-Phenylisoxazoline derivatives of the formula (I), and the use thereof as herbicides, are described. In this formula (I), Xto Xand Rto Rare radicals such as hydrogen, halogen, and organic radicals such as substituted alkyl. W* is carboxyl, cyano or CHO.

3-phenylisoxazolin derivatives with herbicidal action

3-Phenylisoxazoline-5-carboxamides and 3-phenylisoxazoline-5-thioamides of the formula (I) and their use as herbicides and fungicides are described.  In this formula (I), X, Xto X, Rto Rare radicals such as hydrogen, halogen and organic radicals such as substituted alkyl. A is a bond or a divalent unit. Y is a chalcogen.

Herbicidally and fungicidally active 3-phenylisoxazoline-5-carboxamides and 3-phenylisoxazoline-5-thioamides

The invention relates to 17-(1'-propenyl)-17-3&#x2032;-oxidoestra-4-en-3-one derivatives with the general chemical formula I, where the residues Z, R, R, R, R, R, R, Rand Rhave the meanings stated in Claim, and their solvates, hydrates and salts, including all stereoisomers of these compounds. The invention further relates to the use of these derivatives for the production of a medicinal product for oral contraception and for the treatment of pre-, peri- and postmenopausal complaints and medicinal products that contain said derivatives, and in particular application in the aforementioned indications. The derivatives according to the invention have a progestational and in preferred cases additionally an antimineralocorticoid and neutral to slightly androgenic action. 

17-(1'propenyl)-17-3&#x2032;-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative

The 15&#x3b1;,16&#x3b1;-methylene-17-hydroxy-19-nor-17-pregna-4-en-3-one-21-carboxylic acid &#x3b3;-lactone derivatives of the present invention possess progestational efficacy. They have the general chemical formula I, in which Z is selected from the group comprising an oxygen atom, two hydrogen atoms, NOR and NNHSOR, where R is hydrogen, C-C-alkyl, aryl or C-C-aralkyl, Ris hydrogen or halogen, and moreover either: R, Rtogether form methylene or 1,2-ethanediyl or Ris hydrogen and Ris selected from the group comprising hydrogen, C-C-alkyl, C-C-alkenyl or C-C-alkynyl, and Ris selected from the group comprising hydrogen, C-C-alkyl, C-C-cycloalkyl, C-C-alkenyl or C-C-alkynyl, or: Ris hydrogen and Rand R, together, denote a bond, an oxygen or form methylene, Rrepresents hydrogen or C-C-alkyl and in addition include their solvates, hydrates, stereoisomers and salts. 

19-nor-steroid derivatives with a 15&#x3b1;,16&#x3b1;-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives

Growing community of inventors

Berlin, Germany

Thomas Frenzel